Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2013
Good manufacturing practice and data-integrity controversy
The U.S. Food and Drug Administration reported serious problems at Wockhardt’s Aurangabad manufacturing facility, including alleged widespread fraud, data-integrity failures, contamination concerns involving injectable medicines, and other good-manufacturing-practice violations. The agency restricted the facility’s ability to export medicines. The reference material also states that Wockhardt officials repeatedly threatened FDA inspectors.
Cultural association with codeine cough syrup
The Wockhardt name has been used in popular-culture slang because a codeine- and promethazine-containing cough syrup associated with the brand is referenced in discussions of recreational 'lean'. The available material does not identify this as a corporate misconduct finding or a regulatory case against the brand.